WO2011021390A1 - ビスホスホン酸誘導体及びその放射性金属核種標識体 - Google Patents
ビスホスホン酸誘導体及びその放射性金属核種標識体 Download PDFInfo
- Publication number
- WO2011021390A1 WO2011021390A1 PCT/JP2010/005111 JP2010005111W WO2011021390A1 WO 2011021390 A1 WO2011021390 A1 WO 2011021390A1 JP 2010005111 W JP2010005111 W JP 2010005111W WO 2011021390 A1 WO2011021390 A1 WO 2011021390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bisphosphonic acid
- acid derivative
- labeled
- salt
- bone
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 46
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 40
- 229910052751 metal Inorganic materials 0.000 title claims description 20
- 239000002184 metal Substances 0.000 title claims description 20
- 150000001875 compounds Chemical class 0.000 title description 28
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 20
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- -1 64Cu Chemical compound 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 claims description 2
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 238000009825 accumulation Methods 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 229940062527 alendronate Drugs 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- KEOJOAVYGLGAIM-UHFFFAOYSA-N 1-diethoxyphosphorylbutane Chemical compound CCCCP(=O)(OCC)OCC KEOJOAVYGLGAIM-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- IUPNVOAUFBLQME-SGNQUONSSA-L dioxidanium;dioxido-oxo-(phosphonatomethyl)-$l^{5}-phosphane;technetium-99(4+) Chemical compound [OH3+].[OH3+].[99Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O IUPNVOAUFBLQME-SGNQUONSSA-L 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 5
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- IHFVLLMHOWMWGA-UHFFFAOYSA-N 2-bromo-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)C(Br)CCC(=O)OCC1=CC=CC=C1 IHFVLLMHOWMWGA-UHFFFAOYSA-N 0.000 description 4
- ADHGPCATMVZKLP-UHFFFAOYSA-N 4-[4,7-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7-triazonan-1-yl]-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(=O)OC(C)(C)C)CCN(C(CCC(O)=O)C(=O)OC(C)(C)C)CC1 ADHGPCATMVZKLP-UHFFFAOYSA-N 0.000 description 4
- 238000007469 bone scintigraphy Methods 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 206010061728 Bone lesion Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical class OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 2
- 229960004230 oxidronic acid Drugs 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940120146 EDTMP Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Definitions
- the present invention relates to a bisphosphonic acid derivative in which a bisphosphonic acid compound having bone affinity is linked to a cyclic chelate via a spacer, a radionuclide-labeled bisphosphonic acid derivative coordinated with a radionuclide, and a radionuclide-labeled bisphosphonic acid
- the present invention relates to a radioactive bone diagnostic agent or a radioactive bone therapeutic agent containing a derivative as an active ingredient.
- MDP methanediphosphonic acid
- HMDP hydroxymethanediphosphonic acid
- 99mTc 99m technetium
- the organic diphosphonic acid compound labeled with 99mTc currently in use is a radioactive metal 99mTc and organic diphosphonic acid form a polynuclear complex to form a polymer structure, which affects the clearance from blood and soft tissues. There is a high possibility.
- Non-patent Document 1 bone scintigraphy using 18 fluorine (18F), which is a positron (PET) nuclide, has also been reported as a bone metastasis diagnostic agent since the 1960s (Non-patent Document 1).
- Sodium 18 fluoride (18F-Na) was approved as a pharmaceutical product by the US Food and Drug Administration (FDA), but it was inferior to 99mTc in image quality because it was imaged with a normal gamma camera, and it was difficult to obtain.
- FDA US Food and Drug Administration
- 18F-Na PET images are superior in contrast and spatial resolution compared to existing 99mTc preparation images, and 99mTc bone preparations must wait 3 hours after administration.
- the excellent features of 18F-Na / PET such as the fact that 18F-Na can be imaged from 1 hour after administration, have begun to attract attention again.
- a cyclotron is necessary, and it can be performed only at a managed dedicated facility, and there is a problem that these inspection facilities must be installed near the cyclotron.
- 68 gallium (68Ga) the same PET nuclide, is available from a generator using 68Ge / 68Ga and can be easily obtained in the field by a simple milking operation. Therefore, the cyclotron for producing 18F is There is an advantage that is not necessary.
- Non-patent Documents 2 and 3 As a radioactive bone diagnostic agent using 68Ga, 68Ga-ethylenediaminetetramethylenephosphonate (EDTMP), which is a polyphosphate compound, has been reported for the first time (Non-patent Documents 2 and 3). Also reported are attempts to improve clearance performance at an early point after administration using a compound having a chelate site that forms a complex with a bisphosphonic acid compound and a radioactive metal, and application to bone metastasis pain alleviation treatment. (Patent Documents 1 and 2 and Non-Patent Documents 4 to 6), however, are not necessarily effective and have not yet been put into practical use.
- 68Ga has a short half-life of 68 minutes compared to existing radioactive metals, and shortening the time from drug administration to imaging is a very important issue.
- studies on compounds labeled with 68 Ga using 1,4,7-triazacyclononane-N, N ′, N ′′ -triacetic acid (NOTA) as a chelating agent have been reported (Patent Document 3, In Non-Patent Documents 7 and 8), most of the compounds used are peptide compounds, and there are no reports on osteophilic compounds.
- an object of the present invention is to provide a radioactive bone diagnostic agent that gives a high radioactivity accumulation ratio between bone and blood from an early stage after drug administration and enables imaging in a short time after administration.
- the bisphosphonic acid derivative represented by these, or its salt is provided.
- the present invention also provides a radionuclide-labeled bisphosphonic acid derivative or a salt thereof in which a radiometal nuclide is coordinated to the bisphosphonic acid derivative of the above formula (II) or formula (I) or a salt thereof.
- the present invention also provides a radioactive bone diagnostic agent comprising as an active ingredient the radionuclide-labeled bisphosphonic acid derivative or salt thereof, wherein the radionuclide is selected from 62Cu, 64Cu, 67Ga, 68Ga and 111In. It is.
- the present invention also provides a radioactive bone therapeutic agent comprising as an active ingredient the radionuclide-labeled bisphosphonic acid derivative or salt thereof, wherein the radionuclide is selected from 64Cu, 67Cu, 177Lu, 153Sm and 90Y. It is.
- the present invention provides a kit for preparing a diagnostic or therapeutic radiopharmaceutical containing a bisphosphonic acid derivative of the above formula (II) or formula (I) or a salt thereof and adding a radionuclide. It is.
- the present invention also provides the aforementioned radiometal nuclide-labeled bisphosphonic acid derivative or a salt thereof, wherein the radiometal nuclide is selected from 62Cu, 64Cu, 67Ga, 68Ga and 111In, for radiobone diagnosis.
- the present invention also provides the above-mentioned radiometal nuclide-labeled bisphosphonic acid derivative or a salt thereof, wherein the radiometal nuclide is selected from 64Cu, 67Cu, 177Lu, 153Sm and 90Y for radiobone diagnosis.
- the present invention is characterized in that an effective amount of the above-mentioned radionuclide-labeled bisphosphonic acid derivative or a salt thereof, wherein the radionuclide is selected from 62Cu, 64Cu, 67Ga, 68Ga and 111In, is provided to the subject in need.
- a method for diagnosing radioactive bone is provided.
- the present invention provides a radioactive substance characterized in that the radioactive metal nuclide-labeled bisphosphonic acid derivative or a salt thereof, wherein the effective amount of the radiometal nuclide is selected from 64Cu, 67Cu, 177Lu, 153Sm and 90Y, is administered to a necessary subject
- a bone treatment method is provided.
- the radioactive bone diagnostic agent of the present invention is equivalent to the accumulation of bone compared to the conventional radioactive bone diagnostic agent (for example, 99mTc-MDP), the clearance from the blood is fast, so that a high bone / A blood radioactivity accumulation ratio can be obtained, and the time until imaging can be shortened. Furthermore, taking advantage of the property of being a PET nuclide, a tomographic image of the whole body can be easily captured, and an improvement in diagnosis of bone diseases can be expected.
- the conventional radioactive bone diagnostic agent for example, 99mTc-MDP
- the rat biodistribution of 68Ga-NOTA-alendronate, 99mTc-MDP and 18F-Na is shown.
- the rat biodistribution of 68Ga-NOTA-alendronate, 99mTc-MDP and 18F-Na is shown.
- the rat biodistribution of 68Ga-NOTA-alendronate, 99mTc-MDP and 18F-Na is shown.
- a rat imaging image of 99mTc-MDP is shown.
- a rat imaging image of 68Ga-NOTA-alendronate is shown.
- 68B shows a monodel mouse imaging image of local bone metastasis of 68Ga-NOTA-alendronate.
- the bisphosphonic acid derivatives or salts thereof represented by the chemical formulas (II) and (I) of the present invention are useful as precursors for coordinating the radiometal nuclides.
- X represents — (CH 2 ) m CO—.
- m is an integer of 1 to 3. More preferred is — (CH 2 ) 2 CO—.
- Y represents — (CH 2 ) n —.
- n is an integer of 0-4. More preferred Y is — (CH 2 ) 2 — and — (CH 2 ) 3 —, and particularly preferred Y is — (CH 2 ) 3 —.
- the compounds of formula (II) are particularly preferred.
- Examples of the salt of the compound of the formula (II) include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt.
- the compound of formula (I) can be obtained, for example, by the following method. First, an alendronate derivative having a hydroxyl group protected with an ethyl group and a tert-butyldimethylsilyl group (TBS group) and a NOTA derivative having a carboxyl group protected with a tert-butyl group (t-Bu group) are subjected to a condensation reaction. Thereafter, each protecting group is deprotected to produce NOTA-alendronate, which is a bisphosphonic acid derivative of formula (I).
- a bisphosphonic acid derivative having a different methylene chain length between the P—C—P skeleton and the amino group is synthesized by using raw materials having different methylene chain lengths. be able to.
- bisphosphonic acid derivatives having different spacer lengths can be synthesized by using raw materials having different methylene chain lengths.
- the compound of formula (II) or formula (I) is dissolved in a sodium acetate solution or a sodium acetate buffer solution, and 68GaCl 3 eluted from a 68Ge / 68Ga generator is added and reacted, thereby causing a radionuclide labeled bisphosphonic acid derivative. Is obtained.
- a radionuclide-labeled bisphosphonic acid derivative or a salt thereof in which various radionuclide labels are coordinate-bonded can be obtained.
- radioactive metal nuclides used include 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 177Lu, 153Sm, 90Y, and 111In.
- 62Cu, 64Cu, 67Ga, 68Ga, 111In a radionuclide-labeled bisphosphonic acid derivative or a salt thereof useful as a radioactive bone diagnostic agent can be obtained.
- 64Cu, 67Cu, 177Lu, 153Sm, 90Y is used, a radionuclide-labeled bisphosphonic acid derivative or salt thereof useful as a radioactive bone therapeutic agent can be obtained.
- the reaction solution can be used as it is without performing a special purification operation. It can be used as
- the radioactive bone diagnostic agent or radiobone therapeutic agent of the present invention contains a pH adjuster, a surfactant, a stabilizer, a buffer, an excipient and the like within a clinically acceptable range in addition to the active ingredient. May be.
- the bisphosphonic acid derivative of the present invention is provided as an aqueous solution or a lyophilized preparation, and is provided as a kit preparation for preparing a radioactive bone diagnostic agent by coexisting a buffer, a stabilizer and the like in the aqueous solution or lyophilized preparation. I can do it.
- the kit preparation for preparation of a radiodiagnostic agent containing the bisphosphonic acid derivative of the present invention is provided as a lyophilized preparation because it can be prepared by simply adding a 68GaCl 3 solution easily obtained from a 68Ge / 68Ga generator. It is used for administration after dissolving and labeling at the time of use.
- the radioactive bone diagnostic agent or radiobone therapeutic agent of the present invention can be used in the same manner as conventional radiobone diagnostic agents or radiobone therapeutic agents.
- the liquid agent is administered to mammals including humans.
- the dose is 1.85 to 12.3 MBq / kg, preferably 3.1 to 6.2 MBq / kg, as in the conventional radiobone diagnostic agent or radiobone therapeutic agent.
- the dose is appropriately adjusted according to the patient's age, weight, symptoms, administration method, and combination with other agents.
- the therapeutic agent for radiobone of the present invention is useful for the treatment of bone metastases of tumors diagnosed with the diagnostic agent for radiobone of the present invention.
- Example 3 Synthesis of 68 Ga-NOTA-alendronate 67 ⁇ L of sodium acetate buffer (pH 5.5) was added to the reaction vessel, and then 213 ⁇ L of 68 GaCl 3 solution was added, followed by NOTA-alene dissolved in sodium acetate buffer (pH 5.5) Dronate (20 ⁇ L) was added, and the mixture was reacted at 100 ° C. for 10 minutes and allowed to stand at room temperature. Radiochemical purity was analyzed by TLC and HPLC and was obtained with radiochemical purity greater than 95%.
- Example 4 Preparation of 68Ga-NOTA-alendronate synthesis kit formulation NOTA-alendronate was dissolved in disodium phosphate aqueous solution (0.25M) to prepare 0.376 mM aqueous solution, and dispensed in 3 mL aliquots into vials. Then, freeze-drying was performed to prepare a kit preparation for synthesis.
- 6 mL of 68GaCl3 solution was added to the vial, reacted at 150 ° C. for 10 minutes, and allowed to stand at room temperature. Radiochemical purity was analyzed by TLC and HPLC and was obtained with radiochemical purity greater than 95%.
- 68Ga-NOTA-alendronate Compared with 99mTc-MDP, 68Ga-NOTA-alendronate has a rapid loss of radioactivity from blood, and the accumulation in bone shows the same level as 99mTc-MDP. The radioactivity accumulation ratio improved significantly from the early stage after administration. In addition, as shown in the table, 68Ga-NOTA-alendronate showed non-specific accumulation in other organs similar to 99mTc-MDP, and was hardly observed. Further, the same bone / blood radioactivity accumulation ratio as that of 18F-Na was obtained, and it seems to be useful as a PET bone diagnostic agent.
- Example 6 Rat Imaging Experiment Wistar male rats were administered 18.5-37 MBq from the tail vein of rats under anesthesia with 68Ga-NOTA-alendronate and 99mTc-MDP. Imaging was performed with a PET / CT or SPECT camera 60 and 180 minutes after administration.
- FIGS. 68Ga-NOTA-alendronate has a rapid radioactivity loss from blood compared to 99mTc-MDP, so bones are clearly depicted 60 minutes after administration, and bone lesions are observed earlier than 99mTc-MDP after administration. Diagnosis of this is considered possible.
- Example 7 Local bone metastasis model mouse imaging experiment Human prostate cancer-derived cells were transplanted into the mouse right tibia to create a local bone metastasis model. About 6.0 MBq was administered to the model mouse from the tail vein under anesthesia with 68 Ga-NOTA-alendronate. Imaging was performed with PET / CT 60 minutes after administration.
- Example 8 Synthesis of DOTA-alendronate 1,4,7,10, -tetraazacyclododecane-N, N ′, N ′′, N ′ ′′-tetraacetic acid (DOTA) via a spacer DOTA-alendronate linked with alendronate was synthesized, and 68Ga-DOTA-alendronate labeled with 68Ga was synthesized, and the drug performance was compared. DOTA-alendronate was prepared by the steps represented by 12-13 as shown below.
- Example 9 Synthesis of 68 Ga-DOTA-alendronate 67 ⁇ L of sodium acetate buffer (pH 5.0) was added to the reaction vessel, and then 213 ⁇ L of 68 GaCl 3 solution was added, and then DOTA-allene dissolved in sodium acetate buffer (pH 4.5) After adding 20 ⁇ L of the dronate solution and reacting at 100 ° C. for 15 minutes, the solution was left at room temperature. Radiochemical purity was analyzed by HPLC and TLC and was obtained with radiochemical purity greater than 95%.
- Example 10 Distribution of 68Ga-DOTA-alendronate in rats 68Ga-DOTA-alendronate, 99mTc-MDP (product name: Techne MDP injection, FUJIFILM RI Pharma Co., Ltd., 740MBq) / 2 mL) was diluted to 12.3 to 19.8 MBq / mL, and 0.2 mL was administered from the tail vein of anesthetized rats. 120 minutes after the administration, the animals were sacrificed, the organs were removed, and the weight and radioactivity of each were measured. As a percentage of the dose, the% I.D. D. Calculated as / g tissue weight. Table 4 shows the results of measuring the distribution of 68Ga-DOTA-alendronate in rats.
- 68Ga-DOTA-alendronate like 99mTc-MDP, showed high radioactivity accumulation in the bone, but on the other hand, clearance from the blood was delayed, resulting in 2 hours after administration. The bone / blood radioactivity accumulation ratio was not improved.
- the delay in clearance from blood may be derived from the in vivo stability of the 68Ga-DOTA complex.
- 68Ga-NOTA-alendronate can clearly depict bone early after administration, and bone lesions can be diagnosed at an earlier stage. .
- the radioactive bone diagnostic agent of the present invention is equivalent to the accumulation of bone compared to the conventional radioactive bone diagnostic agent (for example, 99mTc-MDP), the clearance from the blood is fast, so that a high bone / A blood radioactivity accumulation ratio can be obtained, and the time until imaging can be shortened. Furthermore, taking advantage of the property of being a PET nuclide, a tomographic image of the whole body can be easily captured, and an improvement in diagnosis of bone diseases can be expected.
- the conventional radioactive bone diagnostic agent for example, 99mTc-MDP
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
現在使用されている99mTcで標識された有機ジホスホン酸化合物は、放射性金属である99mTcと有機ジホスホン酸が多核錯体を形成し、ポリマー構造を作るため、血液、軟部組織からのクリアランスに影響を与えている可能性が高い。
18フッ化ナトリウム(18F-Na)は米国食品医薬品局(FDA)により、医薬品として承認されたが、通常のガンマカメラで撮像されたため、画質的に99mTcより劣っており、また入手の難しさもあり、99mTc骨製剤が出現すると18F-Naは直ちに置き換えられ、骨転移診断用の画像診断剤は現在99mTc製剤が標準的に使用されてきている。しかし、1990年代からPET専用カメラの普及が進み、18F-NaのPET画像が既存99mTc製剤の画像と比較して、コントラスト及び空間分解能に優れている点や99mTc骨製剤では投与後3時間待つ必要があるのに対し、18F-Naでは投与後1時間から撮像可能である点など、18F-Na/PETの優れた特徴が再び注目されるようになった。
但し、18Fを製造するためには、サイクロトロンが必要であり、管理された専用施設でしか行うことが出来ず、またこれらの検査施設をサイクロトロンの近くに設置されなければならないという問題があった。
さらに、68Gaは既存の放射性金属と比べて、半減期が68分と短く、薬剤投与から撮像までの時間短縮が非常に重要な問題である。
また、1,4,7-トリアザシクロノナン-N,N’,N’’-三酢酸(NOTA)をキレート剤に用い、68Gaで標識した化合物に関する研究が報告されている(特許文献3、非特許文献7、8)が、用いられている化合物の殆どはペプチド化合物であり、骨親和性化合物についての報告はない。
また、本発明は、放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれるものである前記の放射性金属核種標識ビスホスホン酸誘導体又はその塩を有効成分とする放射性骨治療剤を提供するものである。
さらに本発明は、上記式(II)又は式(I)のビスホスホン酸誘導体又はその塩を含有し、放射性金属核種を加えることにより、診断用又は治療用の放射性薬剤を調製するキットを提供するものである。
また本発明は、放射性骨診断用の、放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれる前記の放射性金属核種標識ビスホスホン酸誘導体又はその塩を提供するものである。
さらに本発明は、必要な対象者に有効量の放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれる前記の放射性金属核種標識ビスホスホン酸誘導体又はその塩を投与することを特徴とする放射性骨治療方法を提供するものである。
なお、上記アレンドロネート誘導体を合成する際、メチレン鎖の長さの異なる原料を用いることにより、P-C-P骨格とアミノ基の間のメチレン鎖の長さの異なるビスホスホン酸誘導体を合成することができる。また、同様に上記NOTA誘導体を合成する際、メチレン鎖の長さの異なる原料を用いることにより、スペーサーの長さの異なるビスホスホン酸誘導体を合成することができる。
4-アミノ-1-{[(tert-ブチル)-1,1-ジメチルシリル]オキシ}-1,1-ジ(ジエトキシフォスフォリル)-ブタン(4)の合成
化合物(4)は以下に示すように、1~4で表される工程によって調製した。
亜リン酸トリエチル(3.3g)に4-クロロブチリルクロリド(1)(2.82g)を滴下し、撹拌した。反応液にジクロロメタン(100mL)を加えた後、亜リン酸ジエチル(3.0g)を滴下し、撹拌した。反応液にN,N-ジメチルアミノピリジン(2.44g)とtert-ブチルジメチルシリルクロリド(3.32g)を加え、撹拌した。溶媒を留去した後、酢酸エチルに溶解し、塩酸水溶液で洗浄した。乾燥、溶媒留去して得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(2.0g)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:0.21(6H,s),0.91(9H,s),1.35(12H,t,J=7.1Hz),2.15-2.22(4H,m),3.54-3.57(2H,m),4.17-4.26(8H,m).
1-{[(tert-ブチル)-1,1-ジメチルシリル]オキシ}-4-クロロ-1,1-ジ(ジエトキシフォスフォリル)-ブタン(2)(3.7g)のジメチルホルムアミド溶液(50mL)にアジ化ナトリウム(963mg)を加え、撹拌した。反応液に酢酸エチルを加え、水にて洗浄した後、乾燥、溶媒留去して得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(1.4g)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:0.20(6H,s),0.91(9H,s),1.35(12H,t,J=7.1Hz),1.96-2.13(4H,m),3.27(2H,t,J=6.6Hz),4.19-4.26(8H,m).
酢酸エチル(50ml)に溶解した4-アジド-1-{[(tert-ブチル)-1,1-ジメチルシリル]オキシ}-1,1-ジ(ジエトキシフォスフォリル)-ブタン(3)(1.4g)に10%パラジウム炭素(300mg)を加えて、水素気流下、撹拌した。反応液をろ過、濃縮して得られた残渣物をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(780mg)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:0.20(6H,s),0.91(9H,s),1.34(12H,t,J=7.1Hz),1.78-1.82(2H,m),1.99-2.08(2H,m),2.67(2H,t,J=7.1Hz),4.18-4.25(8H,m).
2-[4,7-ジ(カルボキシメチル)-1,4,7-トリアゾナン-1-イル]-5-[(4-ヒドロキシ-4,4-ジフォスフォノブチル)アミノ]-5-オキソペンタノイックアシッド(11:NOTA-アレンドロネート)の合成
化合物(11)は以下に示すように、5~11で表される工程によって調製した。
グルタミン酸-5-ベンジルエステル(7.0g)と臭化カリウム(10.5g)を臭化水素酸水溶液(60mL)に溶解し、撹拌した。反応液に亜硝酸ナトリウム(4.1g)を加え、撹拌した。反応液に濃硫酸(3mL)を加えた後、酢酸エチルにて抽出した。酢酸エチル層を食塩水にて洗浄した後、乾燥、溶媒留去して得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(5.3g)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:2.28-2.44(2H,m),2.58-2.62(2H,m),4.39-4.43(1H,m),5.14(2H,s),7.33-7.37(5H,m).
クロロホルムに溶解した5-(ベンジルオキシ)-2-ブロモ-5-オキソペンタノイックアシッド(5)(5.3g)に、シクロヘキサン(25mL)に溶解したtert-ブチルトリクロロアセトイミド(6.95g)を滴下した。反応後、ジメチルアセトアミド(4mL)を滴下し、次いでボロントリフルオリド・ジエチルエーテル(0.4mL)を滴下し、撹拌した。溶媒を留去し、残ったジメチルアセトアミド層にヘキサンを加えて、抽出した。有機層を乾燥、溶媒留去して得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(4.6g)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:1.47(9H,s),2.25-2.37(2H,m),2.53-2.58(2H,m),4.22-4.26(1H,m),5.13(2H,s),7.32-7.36(5H,m).
クロロホルムに溶解した1,4,7-テトラアザシクロノナン(700mg)にクロロホルムに溶解した5-ベンジル-1-(tert-ブチル)-2-ブロモペンタンジオエイト(6)(643mg)を滴下した。撹拌した後、溶媒を留去して得られた残渣物をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(540mg)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:1.46(9H,s),1.91-2.09(2H,m),2.50-2.58(2H,m),2.65-2.84(12H,m),3.19-3.23(1H,m),5.14(2H,s),7.25-7.36(5H,m).
アセトニトリルに溶解した5-ベンジル-1-(tert-ブチル)-2-(1,4,7-トリアゾナン-1-イル)ペンタノジオエイト(7)(840mg)にtert-ブチルブロモアセテート(579μL)を加えた。反応後、炭酸カリウム(1.63g)を加え、撹拌した。反応液をセライトろ過し、アセトニトリルにて溶出した。ろ液を濃縮し、残渣物をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(1.2g)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:1.48(27H,s),1.87-2.05(2H,m),2.47-2.63(2H,m),2.68-2.94(12H,m),3.16-3.19(1H,m),3.27(4H,s),5.12(2H,m),7.26-7.36(5H,m).
イソプロパノールに溶解した5-ベンジル-1-(tert-ブチル)-2-{4,7-ジ[2-tert-ブトキシ)-2-オキソエチル]-1,4,7-トリアゾナン-1-イル}ペンタンジオエイト(8)(1.2g)に水と10%パラジウム炭素(500mg)を加えて、水素気流下撹拌した。反応液をセライトろ過した後、ろ液を濃縮し、残渣物をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(980mg)を得た。
1H-NMR(溶媒:重クロロホルム、共鳴周波数:400MHz)δ:1.45(18H,s),1.48(9H,s),1.94-2.00(2H,m),2.48-2.56(2H,m),2.65-3.12(12H,m),3.33-3.35(1H,m),3.41(4H,s).
ESI-MS(posi)m/z:544(M+H)+.
ジクロロメタンに4-アミノ-1-{[(tert-ブチル)-1,1-ジメチルシリル]オキシ}-1,1-ジ(ジエトキシフォスフォリル)-ブタン(4)(130mg)と5-(tert-ブトキシ)-4-{4,7-ジ[2-(tert-ブトキシ)-2-オキソエチル]-1,4,7-トリアゾナン-1-イル}-5-オキソペンタノイックアシッド(9)(167mg)を溶解し、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド(58mg)と1-ヒドロキシベンゾトリアゾール(46mg)を加え、室温で24時間撹拌した。溶媒を留去した後、酢酸エチルに溶解して水で洗浄し、乾燥後、溶媒留去して得られた粗成生物をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(220mg)を得た。
ESI-MS(posi)m/z:1002(M+H)+.
アセトニトリルに溶解したtert-ブチル 5-{[4-{[1-(tert-ブチル)-1,1-ジメチルシリル]オキシ}-4,4-ジ(ジエトキシフォスフォリル)ブチル]アミノ}-2-{4,7-ジ[2-(tert-ブトキシ)-2-オキソエチル]-1,4,7-トリアゾナン-1-イル}-5-オキソペンタノエイト(10)(360mg)にブロモトリメチルシラン(2mL)を加えて、室温で24時間撹拌した。次いで、水を加えて室温で3時間撹拌した後、溶媒を留去した。残渣に水及びアセトニトリルを順に加え、析出物をろ取した。得られた固体に1N塩酸水溶液を加え、室温で24時間撹拌した。溶媒を留去した後、残渣に水及びアセトニトリルを順に加え、析出物をろ取し、標題化合物(200mg)を得た。
1H-NMR(溶媒:重水、共鳴周波数:400MHz)δ:1.81-2.16(6H,m),2.45(2H,t,J=7.3Hz),3.11-3.28(14H,m),3.61-3.64(1H,m),3.89(4H,s).
ESI-MS(nega)m/z:302(M-2H)2-,605(M-H)-.
68Ga-NOTA-アレンドロネートの合成
反応容器に酢酸ナトリウム緩衝液(pH5.5)67μLを加え、次いで68GaCl3溶液を213μL添加した後、酢酸ナトリウム緩衝液(pH5.5)に溶解したNOTA-アレンドロネート20μLを加えて、100℃で10分間反応後、室温で放置した。放射化学的純度はTLC及びHPLCにより分析し、放射化学的純度95%以上で得られた。
NMR装置:JNM-AL400型(日本電子株式会社製)
ESI-MS装置:microTOF(Bruker Daltonics社製)
68Ge/68Gaジェネレーター:IGG-100(商品名、Eckert&ZieglerAG社製)
溶出液:0.1N塩酸水溶液
TLC分析条件:
TLCプレート:PEIセルロースプレート(商品名、メルク社製)
展開相:アセトン/2N塩酸水溶液=50/50
検出器:ラジオクロマナイザー(形式:GITA-star、raytest社製)
HPLC分析条件:
カラム:COSMOSIL HILIC(商品名、ナカライテスク社製、サイズ:4.6×150mm)
移動相:5mM エチレンジアミンテトラアセティックアシッド(EDTA)を含む10mMリン酸緩衝液(pH7)/ アセトニトリル=45/55
流速:1.0mL/min
68Ga-NOTA-アレンドロネート合成用キット製剤の作製
リン酸二ナトリウム水溶液(0.25M)にNOTA-アレンドロネートを溶解して、0.376mM水溶液を調製し、3mLずつバイアルに分注した後、凍結乾燥を行い、合成用キット製剤を作製した。68Gaとの反応は、バイアルに68GaCl3溶液を6mL添加し、150℃で10分間反応後、室温で放置した。放射化学的純度はTLC及びHPLCにより分析し、放射化学的純度95%以上で得られた。
ラット体内分布実験
1群3匹のWistar系雄性ラットに68Ga-NOTA-アレンドロネート、99mTc-MDP(製品名:テクネMDP注射液、富士フイルムRIファーマ株式会社製、740MBq/2mL)、18F-Na(横浜市立大学より譲受、90MBq/mL)を5.25~12.3MBq/mLに希釈し、麻酔下ラット尾静脈から0.2mLを投与した。投与15,30,60,120,240分後に屠殺、臓器を摘出し、それぞれの重量と放射能を測定した。投与量に対する割合として、各組織の放射能を組織重量で割った%I.D./g組織重量として算出した。
さらに、18F-Naと同様の骨/血液放射能集積比が得られており、PET骨診断剤として有用であると思われる。
ラットイメージング実験
Wistar系雄性ラットに68Ga-NOTA-アレンドロネート、99mTc-MDPを麻酔下、ラット尾静脈から18.5~37MBqを投与した。投与60、180分後にPET/CT又はSPECTカメラにて撮像を行った。
68Ga-NOTA-アレンドロネートは99mTc-MDPに比べ、血液からの放射能消失が速やかであるため、投与後60分から骨が明瞭に描出されており、99mTc-MDPよりも投与後早期から骨病変の診断が可能であると考えられる。
局所骨転移モデルマウスイメージング実験
ヒト前立腺癌由来細胞をマウス右脛骨に移植し、局所骨転移モデルを作成した。このモデルマウスに68Ga-NOTA-アレンドロネートを麻酔下、尾静脈から約6.0MBqを投与した。投与60分後にPET/CTにて撮像を行った。
68Ga-NOTA-アレンドロネートは骨への集積が高く、血液からの放射能消失が速やかであるため、投与後60分から骨及び矢印部位の病変骨が明瞭に描出されており、既存製剤に比べて投与後早期から骨病変の診断が可能であると考えられる。
DOTA-アレンドロネートの合成
環状キレート化合物である1,4,7,10,-テトラアザシクロドデカン-N,N’,N’’,N’’’-四酢酸(DOTA)にスペーサーを介してアレンドロネートを連結させたDOTA-アレンドロネートを合成し、68Gaで標識した68Ga-DOTA-アレンドロネートを合成し、薬剤性能を比較した。
DOTA-アレンドロネートは以下に示すように、12~13で表される工程によって調製した。
テトラヒドロフランに4-アミノ-1-{[(tert-ブチル)-1,1-ジメチルシリル]オキシ}-1,1-ジ(ジエトキシフォスフォリル)-ブタン(4)(100mg)とトリス-tert-ブチル-DOTA-スクシイミド(100mg)を溶解し、トリエチルアミンを加え、撹拌した。溶媒を留去した後、得られた残渣をシリカゲルカラムクロマトグラフィーにて精製し、標題化合物(120mg)を得た。
ESI-MS(posi)m/z:1030(M+H)+.
アセトニトリルに溶解したtert-ブチル-2-[4,10-ジ[2-(tert-ブトキシ)-2-オキソエチル]-7-(2-{[4-{[1-(tert-ブチル)-1,1-ジメチルシリル]オキシ}-4,4-ジ(ジエトキシフォスフォリル)ブチル]アミノ}-2-オキソエチル)-1,4,7,10-テトラアザシクロドデカニル]アセテート(12)(110mg)にブロモトリメチルシラン(2mL)を加えて、撹拌した。次いで、水を加えて撹拌した後、溶媒を留去した。残渣に水及びアセトニトリルを順に加え、析出物をろ取し、標題化合物(70mg)を得た。
ESI-MS(nega)m/z:316(M-2H)2-,634(M-H)-.
68Ga-DOTA-アレンドロネートの合成
反応容器に酢酸ナトリウム緩衝液(pH5.0)67μLを加え、次いで68GaCl3溶液を213μL添加した後、酢酸ナトリウム緩衝液(pH4.5)に溶解したDOTA-アレンドロネート溶液20μLを加えて、100℃で15分間反応後、室温で放置した。放射化学的純度はHPLC及びTLCにより分析し、放射化学的純度95%以上で得られた。
68Ga-DOTA-アレンドロネートのラット体内分布
1群3匹のWistar系雄性ラットに68Ga-DOTA-アレンドロネート、99mTc-MDP(製品名:テクネMDP注射液、富士フイルムRIファーマ株式会社製、740MBq/2mL)を12.3~19.8MBq/mLに希釈し、麻酔下ラット尾静脈から0.2mLを投与した。投与120分後に屠殺、臓器を摘出し、それぞれの重量と放射能を測定した。投与量に対する割合として、各組織の放射能を組織重量で割った%I.D./g組織重量として算出した。
68Ga-DOTA-アレンドロネートのラット体内分布を測定した結果を表4に示す。
Claims (11)
- 請求項1又は2に記載のビスホスホン酸誘導体又はその塩に放射性金属核種が配位結合した放射性金属核種標識ビスホスホン酸誘導体又はその塩。
- 放射性金属核種が62Cu、64Cu、67Cu、67Ga、68Ga、177Lu、153Sm、90Y及び111Inから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩。
- 放射性金属核種が62Cu、64Cu、67Ga、68Ga及び111Inから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩を有効成分とする放射性骨診断剤。
- 放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩を有効成分とする放射性骨治療剤。
- 請求項1又は2に記載のビスホスホン酸誘導体又はその塩を含有し、放射性金属核種を加えることにより、診断用又は治療用の放射性薬剤を調製するキット。
- 放射性骨診断用の、放射性金属核種が62Cu、64Cu、67Ga、68Ga及び111Inから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩。
- 放射性骨治療用の、放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩。
- 必要な対象者に有効量の、放射性金属核種が62Cu、64Cu、67Ga、68Ga及び111Inから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩を投与することを特徴とする放射性骨診断方法。
- 必要な対象者に有効量の、放射性金属核種が64Cu、67Cu、177Lu、153Sm及び90Yから選ばれる請求項3に記載の放射性金属核種標識ビスホスホン酸誘導体又はその塩を投与することを特徴とする放射性骨治療方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/391,194 US20120148492A1 (en) | 2009-08-20 | 2010-08-19 | Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide |
EP10809736.1A EP2468760B1 (en) | 2009-08-20 | 2010-08-19 | Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide |
JP2011527586A JP5690733B2 (ja) | 2009-08-20 | 2010-08-19 | ビスホスホン酸誘導体及びその放射性金属核種標識体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-190714 | 2009-08-20 | ||
JP2009190714 | 2009-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011021390A1 true WO2011021390A1 (ja) | 2011-02-24 |
Family
ID=43606849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/005111 WO2011021390A1 (ja) | 2009-08-20 | 2010-08-19 | ビスホスホン酸誘導体及びその放射性金属核種標識体 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120148492A1 (ja) |
EP (1) | EP2468760B1 (ja) |
JP (1) | JP5690733B2 (ja) |
WO (1) | WO2011021390A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017039692A (ja) * | 2015-04-20 | 2017-02-23 | タイワン ホパックス ケミカルズ マニュファクチャリング カンパニー リミテッドTaiwan Hopax Chems.Mfg.Co.,Ltd | 骨スキャン用の化合物及びその使用 |
CN107106711A (zh) * | 2014-10-17 | 2017-08-29 | Scv公司 | 用于诊断和治疗骨病的共轭二膦酸盐 |
JP2018524352A (ja) * | 2015-07-07 | 2018-08-30 | ファイブ イレブン ファーマ インコーポレイテッド | Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130123781A1 (en) | 2011-08-24 | 2013-05-16 | California Institute Of Technology | Targeting microbubbles |
US9315524B2 (en) * | 2012-05-07 | 2016-04-19 | Kumar Ranjan Bhushan | Magnetic resonance imaging agents for calcification |
EP3310794A4 (en) | 2015-06-18 | 2019-03-06 | California Institute of Technology | SYNTHESIS AND APPLICATION OF MICROBULLET FORMATION COMPOUNDS |
CN110511244A (zh) * | 2019-07-03 | 2019-11-29 | 济宁医学院 | 一种pet骨显像剂前体及其合成方法 |
US10953023B1 (en) | 2020-01-28 | 2021-03-23 | Applaud Medical, Inc. | Phospholipid compounds and formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02501069A (ja) * | 1987-08-12 | 1990-04-12 | セルテク セラピューティクス リミティド | トリ‐アザ大環状化合物及びそれらの金属錯体 |
JPH05504127A (ja) * | 1989-11-27 | 1993-07-01 | コンキャット リミティド | 常磁性カチオン及びポリホスホネートリガンドの錯体を用いての骨及び関連組織のmri像増強 |
JPH06502645A (ja) * | 1984-10-18 | 1994-03-24 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 金属イオン錯体化のためのポリアザ大環式化合物 |
WO2005053674A1 (en) * | 2003-11-26 | 2005-06-16 | Concat Lp | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639365A (en) * | 1984-10-18 | 1987-01-27 | The Board Of Regents, The University Of Texas System | Gadolinium chelates as NMR contrast agents |
US7211240B2 (en) * | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
CN101528270A (zh) * | 2006-08-28 | 2009-09-09 | 通用电气健康护理有限公司 | 基于68Ga标记的肽的放射性药物 |
-
2010
- 2010-08-19 WO PCT/JP2010/005111 patent/WO2011021390A1/ja active Application Filing
- 2010-08-19 JP JP2011527586A patent/JP5690733B2/ja active Active
- 2010-08-19 EP EP10809736.1A patent/EP2468760B1/en active Active
- 2010-08-19 US US13/391,194 patent/US20120148492A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502645A (ja) * | 1984-10-18 | 1994-03-24 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 金属イオン錯体化のためのポリアザ大環式化合物 |
JPH02501069A (ja) * | 1987-08-12 | 1990-04-12 | セルテク セラピューティクス リミティド | トリ‐アザ大環状化合物及びそれらの金属錯体 |
JPH05504127A (ja) * | 1989-11-27 | 1993-07-01 | コンキャット リミティド | 常磁性カチオン及びポリホスホネートリガンドの錯体を用いての骨及び関連組織のmri像増強 |
WO2005053674A1 (en) * | 2003-11-26 | 2005-06-16 | Concat Lp | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106711A (zh) * | 2014-10-17 | 2017-08-29 | Scv公司 | 用于诊断和治疗骨病的共轭二膦酸盐 |
JP2017538780A (ja) * | 2014-10-17 | 2017-12-28 | エスシーヴイ ゲーエムベーハー | 骨疾患の診断及び治療のためのコンジュゲート化ビスホスホネート |
JP2017039692A (ja) * | 2015-04-20 | 2017-02-23 | タイワン ホパックス ケミカルズ マニュファクチャリング カンパニー リミテッドTaiwan Hopax Chems.Mfg.Co.,Ltd | 骨スキャン用の化合物及びその使用 |
JP2018524352A (ja) * | 2015-07-07 | 2018-08-30 | ファイブ イレブン ファーマ インコーポレイテッド | Hbed−ビスホスホネート、その放射性金属コンジュゲート、およびセラノスティック剤としてのそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
EP2468760B1 (en) | 2014-10-01 |
EP2468760A4 (en) | 2013-01-16 |
EP2468760A1 (en) | 2012-06-27 |
JPWO2011021390A1 (ja) | 2013-01-17 |
JP5690733B2 (ja) | 2015-03-25 |
US20120148492A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5690733B2 (ja) | ビスホスホン酸誘導体及びその放射性金属核種標識体 | |
CA2963433C (en) | Conjugated bisphosphonates for the diagnosis and therapy of bone diseases | |
Suzuki et al. | Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging | |
EP3319643B1 (en) | Hbed-bisphosphonates and radiometal conjugates thereof, useful as theranostic agents | |
Wu et al. | New 68Ga-PhenA bisphosphonates as potential bone imaging agents | |
Srivastava et al. | Synthesis and biological evaluation of newly designed phosphonate based bone-seeking agent | |
HUT73665A (en) | Bifunctional-chelating agents braked with calcogene atoms, pharmaceutical compositions containing them , and use of these compositions in radio- diagnosis and radiotherapy | |
JP2001114792A (ja) | ビスホスホン酸誘導体およびその放射性核種標識体 | |
WO2023019303A1 (en) | Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases | |
Assaad | New amino bisphosphonate compound for skeletal imaging: Comparison study with methylenediphosphonic acid (MDP) and (1-hydroxyethane-1, 1-diyl) diphosphonic acid (HEDP) | |
TWI609875B (zh) | 用於骨掃描的化合物及其用途 | |
CN118119581A (zh) | 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途 | |
CN113557037A (zh) | 用于核医学和放射引导医学的诊断/治疗用途的放射性药物 | |
JP2019085344A (ja) | 放射性フッ素標識化合物 | |
Terry et al. | George P. Keeling, Billie Sherin, Jana Kim, Belinda San Juan, Tilmann Grus, b Thomas R. Eykyn, Frank Rösch, b Gareth Smith, c Philip J. Blower | |
Keeling et al. | tracer with Facile Radiolabelling and Broad Calcium Mineral Affinity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10809736 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011527586 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010809736 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13391194 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |